Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jun;2(2):223-8.
doi: 10.2147/btt.s1980.

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab

George P Kim  1 , Axel Grothey
Affiliations

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab

George P Kim et al. Biologics. 2008 Jun.

Abstract

The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology demonstrating its essential role in colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and thus reduces the incidence of hypersensitivity reactions. But, in several clinical trials, unexpected toxicities have become more apparent, raising concerns of how readily panitumumab can succeed cetuximab. This paper reviews the development of this agent and the pivotal clinical trials that help our understanding of its optimal use in colorectal cancer treatment.

Keywords: bevacizumab; cetuximab; chemotherapy; colorectal cancer; irinotecan; oxaliplatin; panitumumab.

PubMed Disclaimer

References

    1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–34. - PubMed
    1. Barber TD, Vogelstein B, Kinzler KW, et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med. 2004;351:2883. - PubMed
    1. Baselga J, Mendelsohn J. Type I receptor tyrosine kinases as targets for therapy in breast cancer. J Mammary Gland Biol Neoplasia. 1997;2:165–74. - PubMed
    1. Baselga J. Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol. 2001;19:41S–4S. - PubMed
    1. Berlin J, Posey J, Tchekmedyian S, et al. Panitumumab with irino-tecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2007;6:427–32. - PubMed